SCHEMBL15569752

SCHEMBL15569752

CC(C)(C)OC(=O)N1CCc2ccccc2[C@H]1C(=O)N(F)c1ccccc1F

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 15/20 0.42
XIAP P98170 2/20 0.39
ACE P12821 1/20 0.37
TRPM8 Q7Z2W7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15569795 0.90 GHSR (0.49) GHSRXIAP
SCHEMBL16930770 0.90 XIAP (0.37) GHSRXIAPACE
SCHEMBL16930745 0.90 XIAP (0.37) GHSRXIAPACE
SCHEMBL15569060 0.89 GHSR (0.41) GHSRXIAPACETRPM8
SCHEMBL15569740 0.89 GHSR (0.47) GHSRXIAP
SCHEMBL15569088 0.82 XIAP (0.53) XIAPACETRPM8
SCHEMBL30310636 0.79 ACE (0.56) GHSRACE
SCHEMBL18066415 0.79 ACE (0.56) GHSRACE
SCHEMBL29560869 0.79 ACE (0.56) GHSRACE
SCHEMBL605316 0.79 ACE (0.56) GHSRACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422332-B2 Azaheterocycles as BIR2 and/or BIR3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-08-23 US disclosed
US-20150210739-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS HOFFMANN-LA ROCHE INC. 2015-07-30 US disclosed
EP-2885275-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-06-24 EP disclosed
WO-2014026882-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210739-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS BIRC3, BIRC5, BIRC2 GHSR 4702/4885XIAP 4/4885ACE 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.